| Product Unit Size | Cost | Quantity | Stock |
|---|
WZ-4002 inhibits EGFR in a variety of cell lines, including those harboring the T790M gatekeeper mutation. WZ-2004 exhibits anticancer chemotherapeutic activity, inhibiting proliferation of lung adenocarcinoma cells and suppressing tumor growth in animal models.
| Cas No. | 1213269-23-8 |
|---|---|
| Purity | ≥98% |
| Formula | C25H27ClN6O3 |
| Formula Wt. | 494.97 |
| IUPAC Name | N-[3-[5-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]oxyphenyl]prop-2-enamide |
| Solubility | DMSO 13 mg/mL (26.3 mM) Water Insoluble Ethanol Insoluble |
| Appearance | White Powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet |
Nakagawa T, Takeuchi S, Yamada T, et al. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Mol Cancer Ther. 2012 Oct;11(10):2149-57. PMID: 22844075.
Sakuma Y, Yamazaki Y, Nakamura Y, et al. WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors. Lab Invest. 2012 Mar;92(3):371-83. PMID: 22157722.
